undamentalytics Newsletter
Sign in

60 Degrees Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2025, 60 Degrees Pharmaceuticals, Inc. had return on equity of -196.4% and a net margin of -732.5%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin<−999%<−999%<−999%−732.5%−729.9%
Return on equity——−178.5%−196.4%—
Return on assets−476.5%−82.9%−117.4%−132.4%−168.1%
R&D as % of revenue235.5%272.8%820.7%209.5%209.6%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $4m
Short-term assets $4mLonger-term assets $1m
What it owes, and who funded it · $4m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $3m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $149,176 of longer-dated liabilities.
  • More cash than debt $1m of cash against $152,033 of debt.
  • Debt below 40% of shareholders' equity Debt is 6% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$9m of operating cash flow against $152,033 of debt.
  • Operating profit covers interest at least five times over Operating income of −$9m against $7,586 of interest.

From 60 Degrees Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: SXTC vs SXTPSCNX vs SXTPLPCN vs SXTPNTRB vs SXTP

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from 60 Degrees Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 60 Degrees Pharmaceuticals, Inc.